📊 SNTI Key Takeaways
Is Senti Biosciences, Inc. (SNTI) a Good Investment?
Senti Biosciences is a pre-revenue biotech company in severe financial distress with only ~14 months of cash runway at current burn rates. The company burns $7.5M annually while generating just $16K in revenue, supported by a critically thin equity base of $2.6M. While YoY EPS improved 77%, this reflects reduced losses on a catastrophically unprofitable business facing imminent capital constraints.
Senti Biosciences, Inc. Key Strengths (SNTI)
- YoY EPS improvement of 77.3% indicates losses are moderating
- No long-term debt burden limits financial obligations
- Holds $8.9M cash reserves to fund near-term operations
SNTI Stock Risks: Senti Biosciences, Inc. Investment Risks
- Catastrophic cash burn of $7.5M annually against only $16K revenue
- Equity base of $2.6M creates acute bankruptcy and dilution risk
- Current ratio of 1.04x indicates critically tight liquidity with minimal operational flexibility
- Approximately 14-month cash runway forces near-term capital raise or insolvency
- Liabilities of $35.7M approach total assets of $38.2M, leaving no margin for error
Key Metrics to Watch
- Quarterly operating cash burn trend and runway extension
- Clinical trial milestones and regulatory pathway progress
- Capital raise announcements and shareholder dilution impact
Senti Biosciences, Inc. (SNTI) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Senti Biosciences, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
SNTI Profit Margin, ROE & Profitability Analysis
SNTI vs Healthcare Sector: How Senti Biosciences, Inc. Compares
How Senti Biosciences, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Senti Biosciences, Inc. Stock Overvalued? SNTI Valuation Analysis 2026
Based on fundamental analysis, Senti Biosciences, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Senti Biosciences, Inc. Balance Sheet: SNTI Debt, Cash & Liquidity
SNTI Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Senti Biosciences, Inc.'s revenue has declined by 99% over the 5-year period, indicating business contraction. The most recent EPS of $-12.03 indicates the company is currently unprofitable.
SNTI Revenue Growth, EPS Growth & YoY Performance
SNTI Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | N/A | -$4.2M | $-0.14 |
| Q3 2024 | N/A | -$11.2M | $-3.36 |
| Q2 2024 | N/A | -$11.2M | $-2.45 |
| Q1 2024 | N/A | -$12.1M | $-0.26 |
| Q3 2023 | $255.0K | -$11.6M | $-0.34 |
| Q2 2023 | $687.0K | -$11.6M | $-0.42 |
| Q1 2023 | $854.0K | -$11.8M | $-0.42 |
| Q3 2022 | $926.0K | -$11.4M | $-0.38 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Senti Biosciences, Inc. Dividends, Buybacks & Capital Allocation
SNTI SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Senti Biosciences, Inc. (CIK: 0001854270)
📋 Recent SEC Filings
❓ Frequently Asked Questions about SNTI
What is the AI rating for SNTI?
Senti Biosciences, Inc. (SNTI) has an AI grade of D with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SNTI's key strengths?
Claude: YoY EPS improvement of 77.3% indicates losses are moderating. No long-term debt burden limits financial obligations.
What are the risks of investing in SNTI?
Claude: Catastrophic cash burn of $7.5M annually against only $16K revenue. Equity base of $2.6M creates acute bankruptcy and dilution risk.
What is SNTI's revenue and growth?
Senti Biosciences, Inc. reported revenue of $16.0K.
Does SNTI pay dividends?
Senti Biosciences, Inc. does not currently pay dividends.
Where can I find SNTI SEC filings?
Official SEC filings for Senti Biosciences, Inc. (CIK: 0001854270) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SNTI's EPS?
Senti Biosciences, Inc. has a diluted EPS of $-0.14.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is SNTI's fundamental grade?
Based on our AI fundamental analysis in June 2026, Senti Biosciences, Inc. has a D grade with 85% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is SNTI stock overvalued or undervalued?
Valuation metrics for SNTI: ROE of -164.6% (sector avg: 15%), net margin of -26,381.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is SNTI's AI grade for 2026?
Our dual AI analysis gives Senti Biosciences, Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is SNTI's free cash flow?
Senti Biosciences, Inc.'s operating cash flow is $-7.5M, with capital expenditures of $196.0K. FCF margin is -47,981.3%.
How does SNTI compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -26,381.3% (avg: 12%), ROE -164.6% (avg: 15%), current ratio 1.04 (avg: 2).